الفهرس 
Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats
ContentOnly 14 pages are availabe for public view
 |  | from | 163 |  |  |
| | | from | 163 | | |
Abstract
Pathogenesis of immune thrombocytopenia involves 2 major mechanisms: increased platelet destruction and decreased platelet production. Conventional treatments for ITP address only symptoms of increased platelet destruction. Treatment drug therapy is associated with undesirable and unpredictable side effects. Novel therapies have proved its efficacy in managing ITP with few side effects alternative to splenectomy. In this study, the experimental rats showed synergistic effect of co-administration of Romiplostim and Rituximab in normal and diseased groups. This is comparable to clinical data demonstrating that patients whose disease is refractory to conventional treatments may benefit from this combination. Romiplostim activate TPO receptors on megakaryocytes and induce platelet production via the JAK2 and STAT5 kinase pathways, and it has proven efficacious in most refractory patients with ITP. Rituximab acts an anti-CD20-directed cytolytic monoclonal antibody, works by inhibiting B cells from producing autoantibodies as well as reverting T-cell abnormalities in patients who respond to treatment. It is used off-label for the treatment of patients with ITP